{
  "id": 3315,
  "origin_website": "Cell",
  "title": "Synthesis of fluorinated triphenylphosphonium analogs that improve cancer cell selectivity and in vivo detection",
  "procedures": [
    "Step-by-step method details\nStep-by-step method details\nThe following section details the steps needed to synthesize small molecules that modify the phenyl groups of TPP+-conjugated compounds used to target the hyperpolarized mitochondrial membranes to improve selectivity for cancer cells and detection in in vitro and in vivo experimental models.\nPart 1. Chemical synthesis of mitochondria-targeted compounds\nThis section describes how to prepare and synthesize fluorine into TPP+-conjugated small molecules using metformin as an example.\nPart 1a. Preparation of N-[amino(methylsulfanyl)methylidene)guanidine hydroiodide (Scheme 1[href=https://www.wicell.org#sch1])\nTiming: 1 day\nThe following procedure is based on that of Teintze, et al.2[href=https://www.wicell.org#bib2]\nDissolve guanylthiourea (2 g, 16.93 mmol) in ethanol (65 mL) in a 250 mL pressure vessel.\nimgsrc:https://prod-shared-star-protocols.s3.amazonaws.com/protocols/2903-Sch1.jpg\nScheme 1. Synthesis of N-[amino(methylsulfanyl)methylidene)guanidine hydroiodide\nAdd iodomethane (1.25 mL, 2.88 g, 20.31 mmol) to the pressure vessel by dropwise addition.\nHeat the reaction to 40°C for 3 h.\nConcentrate under vacuum using a standard rotary evaporator or similar equipment.\nTriturate the solids with cold diethyl ether.\nCollect solids by vacuum filtration to obtain 4.24 g (96%) of N-[amino(methylsulfanyl)methylidene)guanidine hydroiodide.\nPart 1b. Preparation of tris(3-(trifluoromethyl)phenyl)phosphine (Scheme 2[href=https://www.wicell.org#sch2])\nTiming: 1 day\nThe following procedure is based on that of Herrera, et al.3[href=https://www.wicell.org#bib3]\nSuspend magnesium (0.238 g, 9.77 mmol) in anhydrous diethyl ether (1.9 mL) in a 100 mL round-bottom flask equipped with a reflux condenser.\nimgsrc:https://prod-shared-star-protocols.s3.amazonaws.com/protocols/2903-Sch2.jpg\nScheme 2. Synthesis of tris(3-(trifluoromethyl)phenyl)phosphine\nCritical Step: To initiate the Grignard reaction, start adding a solution of 3-bromobenzotrifluoride (1.24 mL, 2.00 g, 8.89 mmol) dissolved in anhydrous diethyl ether (9 mL) by dropwise addition.\nOptional: If the reaction does not initiate, add a crystal of I2 and/or a drop of dibromomethane. Initiation is observed by bubbles emitting from the magnesium.\nOnce the reaction initiates, continue adding the 3-bromobenzotrifluoride solution from step 8.",
    "Once the addition is complete, heat the reaction at reflux for 2 h.\nCool the reaction to 0°C and add a solution of phosphorus trichloride (0.256 mL, 0.403 g, 2.93 mmol) dissolved in anhydrous diethyl ether (0.75 mL) by dropwise addition.\nHeat the reaction at reflux for 1 h.\nAdd 1 N HCl (25 mL) to quench the reaction.\nExtract the solution with diethyl ether (3 × 25 mL) using a separatory funnel.\nCombine the diethyl ether extracts and wash the combined extracts with brine (25 mL) using a separatory funnel.\nDry the organic phase over Na2SO4, filter, and concentrate under vacuum using a standard rotary evaporator or similar equipment to give the crude product.\nPurify by automated flash chromatography using a 100 g silica gel column (Biotage Sfär Silica HC D-High Capacity Duo 20 μm, 2–20% v/v, ethyl acetate/hexane) to obtain 1.0 g (24%) of tris(3-(trifluoromethyl)phenyl)phosphine as a colorless oil.\nPart 1c. Synthesis of {10-[(carbamimidamidomethanimidoyl)amino]decyl}triphenylphosphonium bromide (Compound 4a)\nTiming: 4 days\nSynthesis of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]triphenylphosphonium bromide 2a (Reaction 1 in Scheme 3[href=https://www.wicell.org#sch3]) (Kalyanaraman, B. WO2018119207).4[href=https://www.wicell.org#bib4]\nimgsrc:https://prod-shared-star-protocols.s3.amazonaws.com/protocols/2903-Sch3.jpg\nScheme 3. Synthesis of TPP+ MMe analogs 4a–4d\nDissolve N-(10-bromodecyl)phthalimide (2.5 g, 6.83 mmol) in anhydrous CH3CN (21 mL) in a 100 mL round bottom flask equipped with a reflux condenser and place under an inert atmosphere of argon or nitrogen.\nAdd triphenylphosphine (1.79 g, 6.83 mmol) to the above solution.\nHeat the reaction mixture at reflux for 18 h.\nMonitor the progress of the reaction by TLC. Elute with 15:85 MeOH:CH2Cl2 on normal phase TLC Silica Gel 60 F254 glass-backed plates.\nWhen the reaction is complete as indicated by the disappearance of the N-(10-bromodecyl)phthalimide by TLC concentrate under vacuum using a standard rotary evaporator or similar equipment.",
    "Purify the residue from step ‘e’ by automated flash chromatography using a 25 g silica gel column (Biotage Sfär Silica HC D-High Capacity Duo 20 μm, 1%–30% v/v, MeOH/CH2Cl2) to obtain 3.98 g (93%) of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]triphenylphosphonium bromide 2a.\nCritical Step: Analyze the product by 1H NMR and confirm that the spectra match those previously reported (Kulkarni, et al., 2021).5[href=https://www.wicell.org#bib5]\nSynthesis of {10-[(carbamimidamidomethanimidoyl)amino]decyl}triphenylphosphonium bromide 4a (Reactions 2 and 3 in Scheme 3[href=https://www.wicell.org#sch3]) (Kalyanaraman, B. WO 2018119207).4[href=https://www.wicell.org#bib4]\nDissolve of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]triphenylphosphonium bromide 2a (1.50 g, 2.39 mmol) in 190 proof ethanol (15 mL) in a 50 mL round-bottom flask equipped with a reflux condenser.\nAdd hydrazine (0.074 mL, 2.39 mmol) to the above solution.\nHeat the solution at reflux for 20 h.\nMonitor the progress of the reaction by TLC. Elute with 20 MeOH/80 CH2Cl2 on amine-treated TLC Silica Gel glass-backed plates (KP-NH TLC Plates).\nOnce the reaction is complete as indicated by the disappearance of the starting material 2a by TLC, concentrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nCritical Step: Filter the reaction mixture to remove the solids.\nConcentrate the filtrate under vacuum using Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nOptional: If solids are still present, suspend the residue in ethanol (10 mL) and filter a second time. Concentrate the filtrate under vacuum using Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nDissolve the residue (0.100 g, 0.201 mmol) in n-butanol (2 mL) in a 30 mL screw cap vial.\nAdd N-[amino(methylsulfanyl)methylidene)guanidine hydroiodide (0.104 g, 0.402 mmol) to the solution.\nHeat at 135°C for 30 min.\nMonitor the progress of the reaction by TLC. Elute with 10:90 MeOH:CH2Cl2 on amine-treated TLC silica gel glass-backed plates (KP-NH TLC Plates).",
    "Once complete as indicated by the disappearance of the starting material 3a by TLC, concentrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nPurify the crude product by automated flash chromatography using an 11 g KP-amino silica gel column (Biotage Sfär KP-Amino-D) eluting with 1%–40% v/v, MeOH/CH2Cl2) to obtain 0.056 g (35%) of 10-[(carbamimidamidomethanimidoyl)amino]decyl}triphenylphosphonium bromide 4a as an amorphous solid.\nCritical Step: Analyze the product by 1H NMR and confirm that the spectra match those previously reported (Kulkarni, et al., 2021).5[href=https://www.wicell.org#bib5]\nPart 1d. Synthesis of (10-(3-carbamimidoylguanidino)decyl)tris(4-(trifluoromethyl)phenyl)phosphonium bromide (Compound 4b)\nTiming: 4 days\nSynthesis of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]tris[4-(trifluoromethyl)phenyl]phosphonium bromide 2b (Reaction 1 in Scheme 3[href=https://www.wicell.org#sch3]) (Kulkarni, et al., 2021).5[href=https://www.wicell.org#bib5]\nDissolve N-(10-bromodecyl)phthalimide (1.5 g, 4.10 mmol) in anhydrous DMF (12.6 mL) in a 30 mL screw cap vial and place it under an inert atmosphere of argon or nitrogen.\nAdd tris(4-trifluoromethyl)phosphine (1.91 g, 4.10 mmol) to the above solution.\nHeat the reaction to 140°C for 48 h.\nMonitor the progress of the reaction by TLC. Elute with 10:90 MeOH:CH2Cl2 on normal phase TLC Silica Gel 60 F254 glass-backed plates.\nOnce the reaction is complete as indicated by the disappearance of N-(10-bromodecyl)phthalimide by TLC, concentrate under vacuum using a standard rotary evaporator or similar equipment.\nPurify the crude product by using a 25 g silica gel column (Biotage Sfär Silica HC D-High Capacity Duo 20 μm, 1%–20% v/v, MeOH/CH2Cl2) to obtain 2.59 g (76%) of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]tris[4-(trifluoromethyl)phenyl]phosphonium bromide 2b.\nCritical Step: Analyze the product by 1H NMR and confirm that the spectra match those previously reported (Kulkarmi, et al., 2021).6[href=https://www.wicell.org#bib6]\nSynthesis of (10-(3-carbamimidoylguanidino)decyl)tris(4-(trifluoromethyl)phenyl)phosphonium bromide (steps 2 and 3 in Scheme 3[href=https://www.wicell.org#sch3]) (Kalyanaraman, B. WO 2018119207).4[href=https://www.wicell.org#bib4]\nDissolve [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]tris[4-(trifluoromethyl)phenyl]phosphonium bromide 2b (2.59 g, 4.10 mmol) in ethanol (19 mL) in a 50 mL round bottom flask equipped with a reflux condenser.",
    "Add hydrazine (0.145 mL, 4.66 mmol) to the above solution.\nHeat the reaction at reflux for 20 h.\nMonitor the progress of the reaction by TLC. Elute with 15:85 MeOH:CH2Cl2 on amine-treated TLC silica gel glass-backed plates (KP-NH TLC Plates).\nCritical Step: Once the reaction is complete as indicated by the disappearance of starting material 2b by TLC, filter the reaction mixture to remove the solids.\nConcentrate the filtrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nOptional: If solids are still present, suspend the residue in ethanol (10 mL) and filter a second time. Concentrate the filtrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nDissolve the residue in n-butanol (3.7 mL) in a 30 mL screw cap vial.\nAdd N-[amino(methylsulfanyl)methylidene)guanidine hydroiodide (0.268 g, 1.03 mmol) to the solution.\nHeat the reaction at 130°C for 3 h.\nConcentrate the reaction under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nPurify the crude product using a 28 g KP-amino silica gel column (Biotage Sfär KP-Amino-D) eluting with 1%–20% v/v, MeOH/CH2Cl2) to obtain 0.224 g (32%) of 10-(3-carbamimidoylguanidino)decyl)tris(4-(trifluoromethyl)phenyl)phosphonium bromide 4b as an amorphous solid.\nCritical Step: Analyze the product by 1H NMR, 19F NMR, and HR-MS and confirm that the spectra match those previously reported (Kulkarni, et al., 2021).5[href=https://www.wicell.org#bib5]\nPart 1e. Synthesis of (10-(3-carbamimidoylguanidino)decyl)tris(3-(trifluoromethyl)phenyl)phosphonium bromide (Compound 4c)\nTiming: 4 days\nSynthesis of (10-(1,3-dioxoisoindolin-2-yl)decyl)tris(3-(trifluoromethyl)phenyl)phosphonium bromide 2c (Reaction 1 in Scheme 3[href=https://www.wicell.org#sch3]) (Kulkarni, et al., 2021).5[href=https://www.wicell.org#bib5]\nDissolve N-(10-bromodecyl)phthalimide (0.500 g, 1.37 mmol) in anhydrous DMF (4.2 mL) in a 30 mL screw cap vial and place it under an inert atmosphere of argon or nitrogen.\nAdd tris(3-trifluoromethyl)phosphine (0.637 g, 1.37 mmol) to the above solution.\nHeat the reaction at 140°C for 51 h.",
    "Monitor the progress of the reaction by TLC. Elute with 10:90 MeOH:CH2Cl2 on normal phase TLC Silica Gel 60 F254 glass-backed plates.\nOnce complete as indicated by the disappearance of N-(10-bromodecyl)phthalimide by TLC, concentrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nPurify the crude product by automated flash chromatography using a 10 g silica gel column (Biotage Sfär Silica HC D-High Capacity Duo 20 μm, 0%–30% v/v, MeOH/CH2Cl2) to obtain 0.442 g (39%) of (10-(1,3-dioxoisoindolin-2-yl)decyl)tris(3-(trifluoromethyl)phenyl)phosphonium bromide 2c.\nSynthesis of (10-aminodecyl)tris[3-(trifluoromethyl)phenyl]phosphonium bromide 4c (Reactions 2 and 3 in Scheme 3[href=https://www.wicell.org#sch3]) (Kalyanaraman, B. WO 2018119207).4[href=https://www.wicell.org#bib4]\nDissolve of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]tris[3-(trifluoromethyl)phenyl]phosphonium bromide 2c (0.442 g, 0.531 mmol) in a 25 mL round-bottom flask equipped with a reflux condenser in ethanol (3.2 mL).\nAdd hydrazine (0.025 mL, 0.796 mmol) to the above solution.\nHeat the reaction at reflux for 19 h.\nMonitor the progress of the reaction by TLC. Elute with 15:85 MeOH:CH2Cl2 on amine-treated TLC silica gel glass-backed plates (KP-NH TLC Plates).\nCritical Step: Once the reaction is complete as indicated by the disappearance of 2c on the TLC filter the reaction mixture to remove the solids.\nConcentrate the filtrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nOptional: If solids are still present, suspend the residue in ethanol (10 mL) and repeat the filtration. Concentrate the filtrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nDissolve the residue (0.069 g, 0.098 mmol) in n-butanol (1 mL) in a 30 mL screw cap vial.\nAdd N-[amino(methylsulfanyl)methylidene)guanidine hydroiodide (0.029 g, 0.113 mmol) to the solution.\nHeat the reaction at 130°C for 30 min.\nMonitor the progress of the reaction by TLC. Elute with 15:85 MeOH:CH2Cl2 on amine-treated TLC silica gel glass-backed plates (KP-NH TLC Plates).",
    "Once the reaction is complete as indicated by the disappearance of the starting material 3c by TLC, concentrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nPurify the crude product by automated flash chromatography using an 11 g KP-amino silica gel column (Biotage Sfär KP-Amino-D) eluting with 1%–20% v/v, MeOH/CH2Cl2) to obtain (10-(3-carbamimidoylguanidino)decyl)tris(3-(trifluoromethyl)phenyl)phosphonium bromide 4c as an amorphous solid.\nCritical Step: Analyze the product by 1H NMR, 19F NMR, and HRMS and confirm that the spectra match those previously reported (AbuEid, et al., 2022).1[href=https://www.wicell.org#bib1]\nPart 1f. Synthesis of [10-(2-carbamimidoylethanimidamido)decyl]tris(4-methoxyphenyl)phosphonium bromide (Compound 4d)\nTiming: 4 days\nSynthesis of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]tris(4-methoxyphenyl)phosphonium bromide 2d (Reaction 1 in Scheme 3[href=https://www.wicell.org#sch3]) (Kulkarni, et al., 2021).5[href=https://www.wicell.org#bib5]\nDissolve N-(10-bromodecyl)phthalimide (0.500 g, 1.37 mmol) in anhydrous CH3CN (4.2 mL) in a 50 mL round-bottom flask equipped with a reflux condenser and place under an inert atmosphere of argon or nitrogen.\nAdd tris(4-methoxyphenyl)phosphine (0.481 g, 1.37 mmol) to the above solution.\nHeat the reaction at reflux for 19 h.\nMonitor the progress of the reaction by TLC. Elute with 10:90 MeOH:CH2Cl2 on normal phase TLC Silica Gel 60 F254 glass-backed plates.\nOnce the reaction is complete as indicated by the disappearance of N-(10-bromodecyl)phthalimide by TLC, concentrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nPurify the crude product by automated flash chromatography using a 25 g silica gel column (Biotage Sfär Silica HC D-High Capacity Duo 20 μm, 0%–30% v/v, MeOH/CH2Cl2) to obtain 0.920 g (93%) of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]tris(4-methoxyphenyl)phosphonium bromide 2d.\nSynthesis of (10-aminodecyl)tris(4-methoxyphenyl)phosphonium bromide 4d (Reactions 2 and 4 in Scheme 3[href=https://www.wicell.org#sch3]) (Kalyanaraman, B. WO 2018119207).4[href=https://www.wicell.org#bib4]\nDissolve of [10-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)decyl]tris(4-methoxyphenyl)phosphonium bromide 2d (0.920 g, 1.28 mmol) in ethanol (8 mL) in a 25 mL round-bottom flask equipped with a reflux condenser.",
    "Add hydrazine (0.074 mL, 1.28 mmol) to the above solution.\nHeat the reaction at reflux for 20 h.\nMonitor the progress of the reaction by TLC. Elute with 15:85 MeOH:CH2Cl2 on amine-treated TLC silica gel glass-backed plates (KP-NH TLC Plates).\nCritical Step: Once the reaction is complete as indicated by the disappearance of the starting material 2d by TLC, filter the reaction mixture to remove the solids.\nConcentrate the filtrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nOptional: If solids are still present, suspend the residue in ethanol (10 mL) and filter a second time. Concentrate the filtrate in vacuo using a Biotage V10 speed evaporator or standard rotary evaporator.\nDissolve the residue (0.150 g, 0.255 mmol) in CH2Cl2 (2.5 mL) in a 30 mL screw cap vial and cool to 0°C.\nAdd hydrogen chloride (0.765 mL, 0.765 mmol, 1M in ethyl ether) by dropwise addition to the above solution.\nStir the reaction at 22°C for 1 h.\nConcentrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nDissolve the residue in anhydrous DMF (1 mL).\nAdd diacyldiamide (0.97 g, 1.47 mmol) to the solution and heat at 160°C for 2 h.\nMonitor the progress of the reaction by TLC. Elute with 15:85 MeOH:CH2Cl2 on amine-treated TLC silica gel glass-backed plates (KP-NH TLC Plates).\nOnce the reaction is complete as indicated by the disappearance of starting material 3d by TLC, concentrate under vacuum using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nPurify the crude product by automated flash chromatography using an 11 g KP-amino silica gel column (Biotage Sfär KP-Amino-D) eluting with 0%–30% v/v, MeOH/CH2Cl2) to obtain 0.114 g (67%) of [10-(2-carbamimidoylethanimidamido)decyl]tris(4-methoxyphenyl)phosphonium bromide 4d as an amorphous solid.",
    "Critical Step: Analyze the product by 1H NMR and HRMS and confirm that the spectra match those previously reported (AbuEid, et al., 2022).1[href=https://www.wicell.org#bib1]\nPart 2a. Treatment of mammalian cells with mitochondria-targeted compounds\nTiming: 2 days\nThis section describes how to use mammalian cell culture as a reductionist approach to validate the functional effects of synthesized fluorinated small molecules.\nNote: Murine pancreas cancer cells were used as a model, but other eukaryotic cell lines were shown in AbuEid et al., 20221[href=https://www.wicell.org#bib1] to be sensitive to both the parent MMe and the fluorinated pCF3-MMe compounds.\nPlate 1 × 107 murine pancreas cancer cells (KPC1242) in individual 10 cm dishes.\nAllow cells to adhere 18–24 h at 37°C in a humidified 5% CO2 incubator.\nAdd 1 mg pCF3-MMe from a 400 mM stock solution in a final volume of 3.2 μL to cells.\nIncubate for 2 h. Remove media.\nFollowing treatment, extract pCF3-MMe with one of the following solvent mixtures:\n9:1 CHCl3:H2O.\n1:1 MeCN:H2O.\n8:2 MeOH:H2O.\nCH2Cl2.\nPlace cells in extraction buffer on a dry ice ethanol bath on an orbital shaker for 20 min.\nScrape cell debris and use a 1 mL sterile plastic pipette to transfer the extraction buffer slurry to a sterile 1.5 mL centrifuge tube.\nCentrifuge for 10 min at 10,000 × g on a standard benchtop microcentrifuge at 22°C.\nRemove the extract buffer supernatant using a 1.0 mL sterile pipette into a 20 mL scintillation vial and store at −80°C.\nRemove the scintillation vial from −80°C and bring it to 22°C.\nEvaporate solvents using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nBefore NMR acquisition, resuspend samples in an equal volume of DMSO-d6.\nPart 2b. Treatment and preparations of mouse tissue with mitochondria-targeted compounds\nTiming: 13 days",
    "This section describes testing synthesized fluorinated MMe analogs as anti-tumor agents in a pre-clinical model system. An in vivo pancreas cancer model is described but other cancer model systems have shown sensitivity to TPP+-conjugated agents, including breast cancer (Cheng, et al., 2013),6[href=https://www.wicell.org#bib6] colon cancer (Boyle, et al., 2018),7[href=https://www.wicell.org#bib7] and melanoma (AbuEid, et al., 2022).8[href=https://www.wicell.org#bib8]\nEngraft male or female C57BL/6J mice with murine cancer cells of the same genetic strain.\nResuspend 1 × 106 murine pancreas cancer KPC1242 cells suspended in DMEM in a final volume of 200 μL.\nInject cells to the subcutaneous space on the right flank of individual mice.\nReturn mice to individual cages with food and water ad libitum.\nOn day 12, treat tumor-bearing mice with 1 mg pCF3-MMe diluted from a 400 mM stock solution in sterile Dulbecco’s PBS injected directly into the tumor mass in a final volume of 50 μL. Treat control mice with vehicle alone.\nHumanely sacrifice tumor-bearing mice 0.5, 2, 4, 6, and 24 h after injection of pCF3-MMe.\nManually mince excised tumors with scissors in 8:2 MeOH:H2O in a 5 mL microcentrifuge tube to extract pCF3-MMe in a total volume of 500 μL.\nPlace minced tumor pieces in a dry ice ethanol bath on an orbital shaker for 20 min.\nCentrifuge for 10 min at 10,000 × g on a standard benchtop microcentrifuge at 22°C.\nRemove the extract buffer supernatant using a 1.0 mL sterile pipette into a 20 mL scintillation vial and store at −80°C.\nRemove the scintillation vial from −80°C and bring it to 22°C.\nEvaporate solvents using a Biotage V10 speed evaporator, standard rotary evaporator, or similar equipment.\nResuspend evaporated samples in an equal volume of DMSO-d6.\nPart 3. 19F NMR acquisition\nTiming: 2 days",
    "This section describes using 19F-NMR to detect and quantify fluorinated small molecules. NMR can be used to detect pCF3-MMe in cell culture or animal tissues as shown in our recent report (AbuEid et al., 2022)1[href=https://www.wicell.org#bib1] and in Figure 1[href=https://www.wicell.org#fig1] testing synthesized fluorinated MMe analogs as anti-tumor agents in pre-clinical model systems.\nimgsrc:https://prod-shared-star-protocols.s3.amazonaws.com/protocols/2903-Fig1.jpg\nFigure 1. Growth inhibitory effects of pCF3-MMe on pancreatic cancer and non-cancer cell types\nLogarithmic dose-response fit curves of KPC1242, Panc-1, AsPC-1, HPSC, and HPNE confluence in response to treatment with pCF3-MMe. IC50 values were calculated from confluence curves on the final day of the study. Figure adapted from AbuEid et al., 2022.1[href=https://www.wicell.org#bib1]\nCollect 19F 1D-NMR spectra of resuspended samples from cell culture or mouse tissue from Parts 2a or 2b using a Bruker Avance-III 500 MHz or similar NMR spectrometer equipped with a 1H&19F/13C/15N-TCI cryoprobe or similar probe capable of 19F acquisition.\nCollect all data at 25°C using a 1D pulse sequence with a 30 flip-angle, 64 transients, and an automatic receiver gain.\nUse TopSpin 3.6.1 to process all spectra and integrate the peak intensity corresponding to the pCF3-MMe 19F signal at -61.6 ppm.\nCreate a standard curve using pCF3-MMe concentrations of 0.25, 0.50, 0.75, 1.0, 1.25, and 1.5 mg/mL and analyze the resulting peak intensities by linear regression.\nUse the standard curve to calculate the pCF3-MMe present per gram of cell pellet or tissue in the processed biological samples."
  ],
  "subjectAreas": [
    "Chemistry",
    "Metabolism",
    "Cancer",
    "Nmr",
    "Model Organisms"
  ],
  "bigAreas": [
    "Biomedical & Clinical Research",
    "Molecular Biology & Genetics"
  ]
}